Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality. LEARN MORE NOVEL TECHNOLOGY NEW SOLUTION Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell cu...
2.https://www.novartis.com/research-development/technology-platforms/cell-therapy/charging-towards-next-generation-car-t 3.亘喜生物官网:https://cn.gracellbio.com/ 4.Ghassemi, S., Durgin, J.S., Nunez-Cruz, S. et al. Rapid manufacturing of non-activated potent CA...
该公司展示了一项同种异体CAR-T细胞治疗复发性高级别胶质瘤的临床研究结果——“An exploratory investigator-initiated trial via intrathecal or intracerebroventricular delivery of B7H3-specific allogeneic universal CAR-T cells in pat...
Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targetingCAR-T cellImmunotherapyadapter CAR-T cellChimeric antigen receptor (CAR)-T therapy holds great promise to sustainably improve cancer treatment. However, currently, a broad applicability of CAR-T cell therapies is ...
Nexcella总裁Gabriel Morris在新闻稿中表示：“NXC-201的ODD代表着我们通过将CAR-T技术过渡到门诊领域，实现计划中的广泛采用，这是一个重大的价值创造步骤。”“ODD for NXC-201 represents a substantial value creating step along our path to unlocking planned wide adoption of CAR-T technology by transitioning...
cells, especially those expressing a chimeric antigen receptor (CAR). In this review, we briefly introduce ICI and BiTEs and mainly focus on the CAR T cell technology, which has lately innovated cancer immunotherapy. The latter strategy uses synthetic CARs to more specifically target cancer cells....
Chimaeric antigen receptor (CAR) T cells can generate durable clinical responses in B-cell haematologic malignancies. The manufacturing of these T cells typically involves their activation, followed by viral transduction and expansion ex vivo for at leas
Chimeric antigen receptor T cells (CAR T cells) are effective against haematologic malignancies. However, in solid tumours, their potency is hampered by local immunosuppression and by the heterogeneous expression of the antigen that the CAR targets. Here
该公司展示了一项同种异体CAR-T细胞治疗复发性高级别胶质瘤的临床研究结果——“An exploratory investigator-initiated trial via intrathecal or intracerebroventricular delivery of B7H3-specific allogeneic universal CAR-T cells in patients with recurrent high-grade gliomas”。
Opportunity:New technology for improving therapy efficiency Multiple myeloma therapy options are limited, although CAR T-cells, modified T cells with lymphocyte-like signaling molecules, have shown promise in targeting genes in malignant cells. Clinical trials are current...